Skip to content
lifestyle.spaziotribu.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Cerenome, Inc.
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
October 27, 2026
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
October 21, 2026
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
October 8, 2026
Cerenome Launches CNSide® CSF Molecular Profile Tests
October 6, 2026
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
September 30, 2026
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
September 25, 2026
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
September 22, 2026
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
September 16, 2026
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
September 10, 2026
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
August 21, 2026
1
2
Next Page
→